JP2022508512A5 - - Google Patents

Info

Publication number
JP2022508512A5
JP2022508512A5 JP2021542069A JP2021542069A JP2022508512A5 JP 2022508512 A5 JP2022508512 A5 JP 2022508512A5 JP 2021542069 A JP2021542069 A JP 2021542069A JP 2021542069 A JP2021542069 A JP 2021542069A JP 2022508512 A5 JP2022508512 A5 JP 2022508512A5
Authority
JP
Japan
Prior art keywords
approximately
composition
present
skin
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021542069A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022508512A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053665 external-priority patent/WO2020069448A1/en
Publication of JP2022508512A publication Critical patent/JP2022508512A/ja
Publication of JP2022508512A5 publication Critical patent/JP2022508512A5/ja
Pending legal-status Critical Current

Links

JP2021542069A 2018-09-28 2019-09-27 ステロイド及び巨大分子の経穴送達 Pending JP2022508512A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862738736P 2018-09-28 2018-09-28
US62/738,736 2018-09-28
PCT/US2019/053665 WO2020069448A1 (en) 2018-09-28 2019-09-27 Transpore delivery of steroids and large molecules

Publications (2)

Publication Number Publication Date
JP2022508512A JP2022508512A (ja) 2022-01-19
JP2022508512A5 true JP2022508512A5 (enExample) 2022-10-05

Family

ID=69949945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542069A Pending JP2022508512A (ja) 2018-09-28 2019-09-27 ステロイド及び巨大分子の経穴送達

Country Status (6)

Country Link
US (3) US20200163977A1 (enExample)
EP (1) EP3856155A4 (enExample)
JP (1) JP2022508512A (enExample)
CN (1) CN113453670A (enExample)
CA (1) CA3114363A1 (enExample)
WO (1) WO2020069448A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113197908A (zh) * 2021-04-28 2021-08-03 四川米兰柏羽医学美容医院有限公司 一种治疗组织疤痕及组织增生的药剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01268648A (ja) * 1988-04-18 1989-10-26 Kuraray Co Ltd 経皮吸収促進剤及びこれを含有する外用医薬組成物
JP2655190B2 (ja) * 1989-06-21 1997-09-17 エスエス製薬 株式会社 コルチコステロイド含有軟膏剤
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US6899897B2 (en) * 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
JP2012532889A (ja) * 2009-07-09 2012-12-20 クレッシェンド セラピューティクス、エルエルシー 創傷治療方法及び傷跡変性方法
WO2011138050A1 (en) * 2010-05-07 2011-11-10 Helmholtz-Zentrum für Infektionsforschung GmbH Method for vaccination
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
KR20140107370A (ko) * 2012-01-09 2014-09-04 알미랄, 에스.에이. 벡사로텐 및 코르티코스테로이드를 포함하는 국소 약학적 조성물
WO2014150074A1 (en) * 2013-03-15 2014-09-25 Massachusetts Institute Of Technology Compositions and methods for nucleic acid delivery
MX2016009057A (es) * 2014-01-10 2017-02-06 Sebacia Inc Vehiculo liquido para suspension de particulas no suministradas.
EP3116473B1 (en) * 2014-03-11 2020-12-30 Promius Pharma, LLC Topical corticosteroid compositions

Similar Documents

Publication Publication Date Title
KR102612453B1 (ko) 항­감염 방법，조성물，및 장치
JP2015163612A (ja) 甲状腺眼症の治療のための方法、組成物及び製剤
JP2020500882A (ja) トレプロスチニルおよびその塩の皮膚投与および経皮投与方法
ZA200706640B (en) Method for a treatment with a medicament combination and medicament combinations suitable for the same
EP1982709A1 (en) Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
JP2015028024A (ja) ４級アンモニウムムスカリン受容体アンタゴニストの噴霧可能組成物
US20120010179A1 (en) Methods of using a thiazole derivative
AU2010220830A1 (en) Medicinal cosmetic lipoatrophy
US20220142915A1 (en) Dental Local Anesthetic Solution
US20250025479A1 (en) Transpore delivery of steroids and large molecules
JP2023538065A5 (enExample)
US6868286B1 (en) Device for a transdermal and phonophoretic combination therapy and the use thereof in a method for medical application
JP2003513028A (ja) 肺疾患を治療するための方法および組成物
RU2539418C1 (ru) Способ лечения местно-распространенного рака орофарингеальной зоны
RU2141854C1 (ru) Способ лечения грибковых заболеваний ногтей
JP2023503283A5 (enExample)
JPWO2012077622A1 (ja) ケロイド又は肥厚性瘢痕の治療剤又は予防剤，気道損傷部の組織肥厚抑制剤
RU2640930C1 (ru) Способ лечения красного плоского лишая в полости рта
CN115697346A (zh) 适应障碍的治疗
Beleri et al. A Comparative Study of Bupivacaine with Dexamethasone and Bupivacaine Alone Under Ultrasound Guided Supraclavicular Brachial Plexus Block for Post-Operative Analgesic Efficacy in Below Mid-Arm Orthopaedic Surgeries
WO2024063661A1 (en) A pharmaceutical composition for topical application and use thereof in the treatment of hemangiomas in children
RU2024118893A (ru) Комбинированная терапия, включающая антитело к il-23 и кортикостероид, для лечения псориаза
HK40088154A (zh) 适应障碍的治疗
KR20250135809A (ko) 요독증성 소양증의 치료
Uysal et al. Different Nebulized Budesonide Dosing Regimens in a Mouse Model of Chronic Asthma